Biosimilars as a strategy to improve sustainability

Affiliations

¹ Medical Oncology, Department of Medicine, University of Verona, A.O.U.I., Verona, Italy.
² Department of Surgery, Oncology and Gastroenterology, University of Padua and Istituto Oncologico Veneto, Padua, Italy.

Editorial

Emilio Bria et al. ESMO Open. 2017.

. 2017 May 29;2(2):e000192.

doi: 10.1136/esmoopen-2017-000192. eCollection 2017.

¹ Medical Oncology, Department of Medicine, University of Verona, A.O.U.I., Verona, Italy.
² Department of Surgery, Oncology and Gastroenterology, University of Padua and Istituto Oncologico Veneto, Padua, Italy.

No abstract available

Keywords: Biosimilars; Breast cancer; Lung cancer.

Conflict of interest statement

Competing interests: None declared.

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.
Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F. Tabernero J, et al. ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. ESMO Open. 2017. PMID: 28848668 Free PMC article. Review.

1. Bennett CL, Sartor OA, Armitage JO, et al. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol 2017;18:22–3. 10.1016/S1470-2045(16)30653-2 - DOI - PubMed
1. Blackstone EA, Fuhr JP. Innovation and competition: will biosimilars succeed?: the creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 2012;9:24–7. - PMC - PubMed
1. Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with Particular reference to oncology prescribers. ESMO Open 2017;1:e000142 10.1136/esmoopen-2016-000142 - DOI - PMC - PubMed
1. Rugo HS, Barve A, Waller CF, et al. Heritage Study Investigators. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 2017;317:37–47. 10.1001/jama.2016.18305 - DOI - PubMed
1. Bruzzi P, Del Mastro L, Sormani MP, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 2005;23:5117–25. 10.1200/JCO.2005.02.106 - DOI - PubMed